Search research articles
Contact Us
Filters
Showing results (11-20 of 16) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 16 results.
World Journal of Surgical Oncology
|
June 28, 2012
Outcome analysis of breast cancer patients who declined evidence-based treatment
Kurian Joseph, Sebastian Vrouwe, Anmmd Kamruzzaman, et al.
BMC Genomics
|
September 30, 2015
Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer
Preethi Krishnan, Sunita Ghosh, Bo Wang, et al.
Journal of Clinical Pathology
|
January 25, 2011
Inappropriate calibration and optimisation of pan-keratin (pan-CK) and low molecular weight keratin (LMWCK) immunohistochemistry tests: Canadian Immunohistochemistry Quality Control (CIQC) experience
Maria Copete, John Garratt, Blake Gilks, et al.
American Journal of Clinical Pathology
|
February 16, 2010
Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests
, Emina Emilia Torlakovic, Robert Riddell, et al.
BMJ Open
|
September 19, 2019
Comparing docosahexaenoic acid (DHA) concomitant with neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone in the treatment of breast cancer (DHA WIN): protocol of a double-blind, phase II, randomised controlled trial
Marnie Newell, John R Mackey, Gilbert Bigras, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM
|
April 14, 2009
Implementation of a Canadian external quality assurance program for breast cancer biomarkers: an initiative of Canadian Quality Control in immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee/Immunohistochemistry
Jefferson Terry, Emina Emilia Torlakovic, John Garratt, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 16) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 16 results.
World Journal of Surgical Oncology
|
June 28, 2012
Outcome analysis of breast cancer patients who declined evidence-based treatment
Kurian Joseph, Sebastian Vrouwe, Anmmd Kamruzzaman, et al.
BMC Genomics
|
September 30, 2015
Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer
Preethi Krishnan, Sunita Ghosh, Bo Wang, et al.
Journal of Clinical Pathology
|
January 25, 2011
Inappropriate calibration and optimisation of pan-keratin (pan-CK) and low molecular weight keratin (LMWCK) immunohistochemistry tests: Canadian Immunohistochemistry Quality Control (CIQC) experience
Maria Copete, John Garratt, Blake Gilks, et al.
American Journal of Clinical Pathology
|
February 16, 2010
Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests
, Emina Emilia Torlakovic, Robert Riddell, et al.
BMJ Open
|
September 19, 2019
Comparing docosahexaenoic acid (DHA) concomitant with neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone in the treatment of breast cancer (DHA WIN): protocol of a double-blind, phase II, randomised controlled trial
Marnie Newell, John R Mackey, Gilbert Bigras, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM
|
April 14, 2009
Implementation of a Canadian external quality assurance program for breast cancer biomarkers: an initiative of Canadian Quality Control in immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee/Immunohistochemistry
Jefferson Terry, Emina Emilia Torlakovic, John Garratt, et al.
Page
of 2